🟢 Arcturus Therapeutics is trading 5.4% up today after Leerink raised its target to $19

Arcturus Therapeutics is trading at $13.57, up 5.44%, with Leerink Partners’ analyst update potentially supporting the move.

• On October 9, 2026, Leerink Partners maintained its Outperform rating and raised its price target from $13 to $19.
• The move comes as biotech ETF XBI is down 2.04%, so sector weakness does not explain the rise.
• The supplied price context does not include intraday volume.